Clinical Research Directory

Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome

This Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety (whether there are any side effects), tolerability (if it does cause side effects, how well your body handles them), pharmacokinetics (PK) (how a drug is taken into your body, spread throughout, broken down, and eliminated), clinical activity (does the drug make patients feel better), immunogenicity (how the immune system responds to the drug), and serum virus neutralizing antibody response (antibodies that block a virus from infecting cells) of VYD2311, the investigational monoclonal antibody being studied, in adults with Long-COVID or Post-Vaccination Syndrome. Participants will receive an intravenous (IV) infusion on Day 1 of either the investigational drug or placebo followed by two intramuscular (IM) injections (a shot in the upper arm), one on day 30 and the other on Day 60. The IM injections will also either be investigational drug or placebo. The participants will be then asked to complete a 30-day follow up period and end the study on day 90.

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech). Investigators will monitor reactogenicity and measure the immune response to the third dose.